伊立替康和紫杉醇联合治疗复发上皮性卵巢癌的疗效观察

Efficacy Observation of Irinotecan Combined with Paclitaxel in the Treatment of Recurrent Epithelial Ovarian Cancer

目的观察伊立替康和紫杉醇联合治疗复发上皮性卵巢癌的疗效。方法选取2011年8月至2013年8月我院收治的50例上皮性卵巢癌患者,依据随机数字表法将这些患者分为两组,即观察组(25例)和对照组(25例)。给予对照组患者单纯伊立替康治疗,给予观察组患者伊立替康和紫杉醇联合治疗。结果观察组患者的中位肿瘤进展时间明显比对照组长(P<0.05),治疗的总有效率88.0%(22/25)明显比对照组60.0%(15/25)高(P<0.05),粒细胞减少和血小板减少发生率80.0%(20/25)、28.0%(7/25)均明显比对照组48.0%(12/25)、4.0%(1/25)高(P<0.05)。结论伊立替康和紫杉醇联合治疗复发上皮性卵巢癌的疗效良好。

Objective To study the clinical efficacy of the combination of paclitaxel and irinotecan in the treatment of recurrent epithelial ovarian cancer. Method 50 cases of patients with epithelial ovarian cancer treated in our hospital from August 2011 to August 2013 were selected and randomly divided into observation group（ 25 cases） and control group（ 25 cases）. The control group was given irinotecan only,while the observation group was given both irinotecan and paclitaxel. Results The median time of tumor progression of the observation group was obviously longer than that of the control group（ P 〈 0. 05）,the total effective rate was 88. 0%（ 22/25）,which was significantly higher than 60. 0%（ 15/25） of the control group（ P〈0. 05）; the occurrence rates of granulocytopenia and thrombocytopenia were 80. 0%（ 20/25） and 80. 0%（ 7/25）,and both were significantly higher than 48. 0%（ 12/25） and4. 0%（ 1/25） of the control group（ P〈0. 05）. Conclusions The combination of irinotecan and paclitaxel is effective in the treatment of recurrent epithelial ovarian cancer.